University of Gothenburg

2026-03-04 Oncorena is pleased to announce that French and Portuguese regulatory authorities have granted approval to expand the Company’s Phase I/II clinical study, Oncorella-1 (NCT05287945; ONC001-CL-001), to France and Portugal. Oncorena is pleased to announce that French and Portuguese regulatory authorities have granted approval to expand the Company’s Phase I/II clinical study, Oncorella-1 (NCT05287945; ONC001-CL-001), to France and Portugal. Oncorella-1 is an open-label, single-arm study evaluating the safety, tolerability, and anti-tumor activity of Oncorena’s drug candidate ONC175 (orellanine) in patients with metastatic clear-cell or papillary renal cell carcinoma who are dependent on chronic dialysis. The study is currently ongoing at Karolinska University Hospital (Stockholm, Sweden) and The University of Texas MD Anderson Cancer Center (Houston, Texas, USA). The expansion to France and Portugal marks an important step in increasing access to the study for a patient population with significant unmet medical need. Börje Haraldsson, CEO and Co-founder of Oncorena, comments: Börje Haraldsson “Regulatory approvals in France and Portugal represent an important milestone for Oncorena and, most importantly, for patients with metastatic renal cell carcinoma who depend on chronic dialysis and have very limited treatment options. By expanding Oncorella-1 to additional European countries, we aim to improve patient access to the study and accelerate the generation of clinical data for ONC175 as a potential new treatment option for this underserved population.” For more information, please contact Börje Haraldsson, M.D., Ph.D., CEO, and CSO Oncorena AB E-mail: borje.haraldsson@oncorena.com Phone: +46 70 267 9544 For more information, please contact Börje Haraldsson, .............................................. About ONC175 ONC175 is an investigational drug product under development that contains synthetically produced orellanine as active ingredient. Orellanine is highly specific to the kidney and induces irreversible renal failure. It is clinically well-known that orellanine does not affect organs other than the kidneys. In pioneering preclinical studies ONC175 demonstrated a powerful and highly organ-specific mode of action capable of eradicating human metastatic renal cancer cells. The primary goal is to develop ONC175 as a potential curative treatment of metastatic renal cell carcinoma in patients with no remaining kidney function, i.e., patients on dialysis. About ONC175 About kidney cancer Approximately 400,000 patients are diagnosed with kidney cancer globally every year according to the WHO. The disease can often be cured by surgery if detected early, but the prognosis is less favorable if there are metastases. Today, the disease is treated with various types of targeted and immuno-active drugs, that seldom are curative. There is therefore a great and urgent unmet medical need for new, effective and safe drugs. About kidney cancer About Oncorena Oncorena AB is a Swedish pharmaceutical company headquartered in Lund. The company develops a new potential breakthrough treatment for patients with metastatic renal cancer. The treatment is based on research led by professor Börje Haraldsson at the University of Gothenburg, Sweden. The project was initially developed with support from Vinnova, Sweden’s Innovation Agency, GU Ventures at the University of Gothenburg and private business angels. Today Oncorena is financed by the investment companies HealthCap, Linc AB and Fåhraeus Startup and Growth AB. For more information, please visit Oncorena’s website at www.oncorena.com About Oncorena

THURSDAY, Feb. 12, 2026 -- Having irritable bowel syndrome (IBS) at age 16 years is the strongest adolescent risk factor for IBS at age 24 years, and 33.6 percent of those with IBS at 16 years still meet the criteria at age 24 years, according to a study published online Jan. 30 in Gastroenterology . Jessica Sjölund, M.D., from Sahlgrenska Academy at the University of Gothenburg in Sweden, and colleagues used data from the Swedish BAMSE birth cohort, which followed 4,089 individuals born in the mid-1990s from birth through young adulthood to examine adolescent risk factors for the presence of IBS at age 24 years and factors associated with IBS persistence from age 16 to 24 years. Exposures were mainly measured at age 16 years. The analysis included 2,539 participants from the original cohort. The researchers found the prevalence of IBS was 10.0 percent at age 24 years; associations were seen for female sex, higher perceived stress , atopic eczema, lifetime migraine or depression, and lower health-related quality of life with IBS at age 24 years. IBS at age 16 years was the strongest adolescent risk factor for IBS at age 24 years. Functional abdominal pain, self-perceived psychological distress and impaired overall health, food hypersensitivity, and short sleep duration were also adolescent factors associated with higher odds of adult IBS. Overall, 33.6 percent of adolescents with IBS at age 16 years still met IBS criteria at age 24 years. There was a strong association for parental IBS symptoms with IBS persistence; no other factors reached statistical significance. "Our results show that IBS in adolescence is not a static condition," Sjölund said in a statement. Several authors disclosed ties to the biopharmaceutical industry. Abstract/Full Text

WEDNESDAY, Feb. 4, 2026 — For many teenagers, the cramping and discomfort of irritable bowel syndrome (IBS) can feel like a life sentence. But a new long-term study offers good news: A majority of adolescents with the condition will likely enter adulthood symptom-free. Researchers from the University of Gothenburg and Karolinska Institute in Sweden followed more than 2,500 individuals born in the 1990s to track how their digestive health changed as they became adults. Participants were evaluated at age 16 and again at age 24 using standard medical assessments for IBS. The results, published recently in the journal Gastroenterology , suggest that digestive health is more flexible than previously thought. Two-thirds of the 16-year-olds who initially met the criteria for IBS no longer had the condition eight years later, the study found. "Our results show that IBS in adolescence is not a static condition," said lead author Jessica Sjölund , a research physician in gastroenterology at the University of Gothenburg in Sweden. "For many, symptoms improve over time, and at the same time we can now better identify those at a greater risk of persistent problems," she added in a news release. While the outlook is positive for many, 34% of young adults saw their IBS symptoms persist. Researchers were able to tease out of some of the factors that predicted ongoing IBS symptoms for this group. The strongest predictor of having IBS at age 24 was having a diagnosis at age 16. Other factors that increased the risk of IBS continuing into a person's 20s included high levels of psychological stress, poor sleep quality, food hypersensitivities and a generally lower rating of one's own health. Family history also played a major role. Teenagers with at least one parent suffering from IBS were much more likely to have lingering issues. This connection suggests that a mix of genetics and shared household habits may contribute to the disease, researchers noted. Researchers didn’t find a significant link to persistent IBS for adolescent functional dyspepsia , a form of upset stomach without a definite cause. Nor did they identify a link between persistent IBS and stuffy or runny nose (rhinitis); exposure to furred pets; and six or more antibiotic prescriptions during adolescence and early adulthood. Early intervention is key, researchers said. Because many of these risk factors are related to lifestyle and mental well-being, the findings suggest the teen years are a significant window of opportunity to change the course of the disease. "Early interventions during adolescence related to sleep, mental well-being and gastrointestinal disorders, as well as interventions aimed at families with clustering of IBS, could reduce the risk of long-term symptoms later in life," study co-author Dr. Magnus Simrén said in a news release. He’s a professor of gastroenterology at the University of Gothenburg. Experts suggest that by focusing on digestive health, stress management and better sleep hygiene, families could turn a potentially lifelong struggle into a temporary hurdle. Sources University of Gothenburg, news release, Feb. 2, 2026 Gastroenterology, Jan. 13, 2026